— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.
— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.
— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint brands drove sales of companion animal products higher by 15%.
— International revenue grew 9% on higher sales across key dermatology portfolio and in certain parasiticides, including Simparica and the Revolution/Stronghold franchise, as well as growth across key markets in Western Europe and in China.
— For full-year 2020, the company expects operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income.
— For the full year 2020, the company expects revenue in the range of $6.65-6.8 billion, EPS of $3.53-3.65 and adjusted EPS of $3.90-4.00. The consensus estimates EPS of $4.01 on revenue of $6.7 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
